A 2001 New Jersey General Assembly · 2026-2027 Regular Session

Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.

This bill exempts drug manufacturers and distributors from New Jersey's pharmacy licensing requirements when distributing dialysate drugs and devices used for home dialysis treatment of end-stage renal disease patients. It directly affects dialysis manufacturers, distributors, and patients receiving home dialysis, allowing them to bypass standard pharmacy licensing rules under six specific conditions. Key provisions include requiring FDA approval, direct delivery only upon physician orders, original sealed packaging, and mandatory weekly quality checks by a consultant pharmacist. The law ensures these products are handled safely while streamlining access for patients needing home dialysis.

Issues: ✓ Healthcare

Bill status in committee 1 of 4 stages cleared

Introduction

Jan 2026

Committee Review

Floor Vote

Governor

Introduced Jan 13, 2026 Last action Jun 18, 2026

Maddy AI version diff · 1 comparison

What changed between versions

Technical Review Of Prefiled Bill → Introduced · 4 edits · Jan 13, 2026

MODERATE

This is a transition from the prefiled technical review version to the introduced version of Assembly Bill 2001. The substantive policy text remains essentially unchanged. The main additions are administrative: removal of the technical review designation, removal of co-sponsor names, and addition of a summary statement at the end describing the bill's purpose.

TECHNICAL

The bill header changed from 'A2001 TR' to 'A2001', indicating it moved out of technical review status into formal introduction.

Co-sponsor information (Assemblymen Scharfenberger and Guardian) was removed from the introduced version.

The status line changed from 'As reported by the Assembly Regulated Professions Committee with technical review' to 'Introduced Pending Technical Review by Legislative Counsel.'

SCOPE

A STATEMENT section was added at the end summarizing the bill's purpose: exempting drug manufacturers and wholesale drug distributors from pharmacist licensing requirements when distributing dialysate drugs or devices to patients with end-stage renal disease, subject to six conditions including FDA approval, proper registration, sealed packaging, delivery only upon physician order, delivery to specified recipients, and periodic pharmacist oversight.

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Jun 18, 2026

Lower · Passed

Reported out of Assembly Committee, 2nd Reading

lower

Jun 18, 2026

Committee

Transferred to Assembly Health Committee

lower

Feb 12, 2026

Committee

Reported and Referred to Assembly Oversight, Reform and Federal Relations Committee

lower

Jan 13, 2026

Introduced

Introduced, Referred to Assembly Regulated Professions Committee

lower

1 primary · 2 co-sponsors